CNBCLean R·
Goldman says this biotech stock will be a winner thanks to a one-of-a-kind treatment
Hemab Therapeutics is likely to gain ground as its treatment for a pair of rare bleeding disorders shows signs of efficacy, per Goldman Sachs.
Read at CNBC →